Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 74, Issue 2, 2010, Pages 233-238

  Visser, Marinella R ^a   Baert, Lieven ^b   Klooster, Gerben van 't ^c   Schueller, Laurent ^b   Geldof, Marian ^e   Vanwelkenhuysen, Iris ^f   de Kock, Herman ^d   De Meyer, Sandra ^d   Frijlink, Henderik W ^a   Rosier, Jan ^b   Hinrichs, Wouter L J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Chem Pharm Development   (Belgium)

^c Preclinical Development   (Belgium)

^d Tibotec bvba   (Belgium)

^e Tibotec bvba   (Belgium)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Absorption; BCS Class IV; Inulin solid dispersion; Pharmacokinetics; Ritonavir; TMC240

Indexed keywords

INULIN; MACROGOL 400; PROTEINASE INHIBITOR; RITONAVIR; TMC 240; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSIBLE TABLET; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG POTENTIATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN;

ANIMALS; BENZOTHIAZOLES; DOGS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; INTESTINAL ABSORPTION; INULIN; MALE; POLYETHYLENE GLYCOLS; RITONAVIR; SOLUBILITY; SULFONES; SUSPENSIONS; TABLETS;

EID: 75749106962     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.10.004     Document Type: Article

References (21)

1. FDA, Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system, , August 2000 (accessed May 2009).
2. Ku M.S. Use of the biopharmaceutical classification system in early drug development. AAPS J. 10 (2008) 208-812
3. Lobenberg R., and Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50 (2000) 3-12
4. Ali A.A., and Gorashi A.S. Absorption and dissolution of nitrofurantoin from different experimental formulations. Int. J. Pharm. 19 (1984) 297-306
5. Fawaz F., Bonini F., Guyot M., Bildet J., Maury M., and Lagueny A.M. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complexes in rabbits. Int. J. Pharm. 19 (1996) 271-275
6. Vasconcelos T., Sarmento B., and Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 12 (2007) 1068-1075
7. Leuner C., and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50 (2000) 47-60
8. Craig D.Q. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int. J. Pharm. 231 (2002) 131-144
9. Keck C.M., and Muller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 62 (2006) 3-16
10. Huang L.F., and Tong W.Q. Impact of solid state properties on developability assessment of drug candidates. Adv. Drug Deliv. Rev. 56 (2004) 321-334
11. Serajuddin A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88 (1999) 1058-1066
12. van Drooge D.J., Hinrichs W.L.J., and Frijlink H.W. Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions. J. Control Release 97 3 (2004) 441-452
13. P. Srinarong, S. Kouwen, M.R. Visser, W.L.J. Hinrichs, H.W. Frijlink, Effect of drug-carrier interaction in solid dispersions on dissolution behavior, Pharm. Dev. Techn. Available online October 5th, doi: 10.3109/10837450903286529.
14. de Waard H., Hinrichs W.L.J., Visser M.R., Bologna C., and Frijlink H.W. Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated. Int. J. Pharm. 349 (2008) 66-73
15. Srinarong P., Faber J.H., Visser M.R., Hinrichs W.L.J., and Frijlink H.W. Strongly enhanced dissolution rate of fenofibrate by incorporation of superdisintegrants in solid dispersion tablets containing a high drug load. Eur. J. Pharm. Biopharm. 73 (2009) 154-161
16. Zijlstra G.S., Rijkeboer M., van Drooge D.J., Sutter M., Jiskoot W., van de Weert M., Hinrichs W.L.J., and Frijlink H.W. Characterization of a cyclosporine solid dispersion for inhalation. AAPS J. 9 (2007) E190-E199
17. van Drooge D.J., Hinrichs W.L.J., Wegman K.A., Visser M.R., Eissens A.C., and Frijlink H.W. Solid dispersions based on inulin for the stabilisation and formulation of delta 9-tetrahydrocannabinol. Eur. J. Pharm. Sci. 21 (2004) 511-518
18. Surleraux D.L.N.G., Tahri A., Verschueren W.G., Pille G.M.E., De Kock H.A., Jonckers T.H.M., Peeters A., De Meyer S., Azijn H., Pauwels R., De Bethune M.-P., King N.M., Prabu-Jeyabalan M., Schiffer C.A., and Wigerinck P.B.T.P. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48 (2005) 1965-1973
19. Youle M. Overview of boosted protease inhibitors in treatment-experiences HIV-infected patients. J. Antimicrob. Chemother. 60 (2007) 1195-1205
20. Granero G.E., Ramachandran C., and Amidon G.L. Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev. Ind. Pharm. 31 (2005) 917-922
21. van Drooge D.J., Hinrichs W.L.J., and Frijlink H.W. Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent. J. Pharm. Sci. 93 (2004) 713-725